Publications by authors named "S Hedau"

Background: Resveratrol has demonstrated its ability to regulate BRCA1 gene expression in breast cancer cells, and previous studies have established the binding of MBD proteins to BRCA1 gene promoter regions. However, the molecular mechanism underlying these interactions remains to be elucidated. The aimed to evaluate the impact of MBD proteins on the regulation of BRCA1, BRCA2, and p16 genes and their consequential effects on breast cancer cells.

View Article and Find Full Text PDF

Objective: To triage low-grade cervical smears (ASCUS/LSIL) by HPV 16/18 genotyping and dual staining with p16/Ki67 and to compare the sensitivity and specificity of these two triage methods for detection of high-grade cervical intraepithelial neoplasia (HGCIN).

Methods: In this prospective cross-sectional study, we evaluated a total of 89 women with low-grade smears (54 ASCUS, 35 LSIL) recruited from a tertiary care hospital. All patients underwent colposcopy guided cervical biopsy.

View Article and Find Full Text PDF

Abemaciclib (Ab) and palbociclib (Pb) are CDK4/6 inhibitors used to cure advanced breast cancer (BC). However, acquired resistance is a major challenge. The molecular mechanisms and signature proteins of therapy resistance for Ab and Pb drugs need to be explored.

View Article and Find Full Text PDF
Article Synopsis
  • Atherosclerotic cardiovascular disease significantly affects dialysis patients, who experience lower lipid levels and higher vascular complications, a phenomenon known as reverse epidemiology.
  • In a multicentric study, researchers analyzed lipid profiles in dialysis patients, noting significant changes in lipid levels pre- and post-dialysis and examining the impact of various factors including statin use and dialysis protocols.
  • The study concludes that low lipid levels are primarily due to dilutional hypolipidemia and suggests using corrected lipid measurements for better risk assessment and treatment planning in this patient population.
View Article and Find Full Text PDF

Exploration of an efficient dual-drug based nanocarrier with high drug loading capacity, specific targeting properties, and long-term stability is highly desirable in cancer therapy. Metal-organic frameworks (MOFs) have proven to be a promising class of drug carriers due to their high porosity, crystalline properties with defined structure information, and their potential for further functionalization. To enhance the drug efficacy as well as to overcome the burst effect of drugs, here we synthesized a pH responsive folic acid (FA) and graphene oxide (GO) decorated zeolitical imidazolate frameworks-8 (GO-FA/ZIF-8), for targeted delivery of doxorubicin (DOX) and cyclophosphamide (CP), simultaneously.

View Article and Find Full Text PDF